Current guidelines on management of HIV-infected pregnant women: impact on mode of delivery

Eur J Obstet Gynecol Reprod Biol. 2008 Aug;139(2):127-32. doi: 10.1016/j.ejogrb.2007.12.007. Epub 2008 Feb 8.

Abstract

Objective: To evaluate acceptance, feasibility and difficulties in the application of a policy of vaginal delivery in selected cases in HIV-infected women.

Study design: HIV-infected women delivering March 2002 to December 2004 and enrolled in a prospective observational study in a University hospital tertiary care center were included. A vaginal delivery was not considered if labor before 36 weeks of pregnancy, preterm premature rupture of membranes, on non-highly active antiretroviral therapy (HAART) or viral load >1000copies/mL. Main outcome measures were mode of delivery, prematurity, acceptance of vaginal delivery and mother-to-child transmission of HIV infection.

Results: The study included 91 pregnancies, with a total of 95 fetuses. Eighty percent (n=73) of women knew their HIV infection status before becoming pregnant and 57 (63%) were on HAART at conception. Median gestational age at delivery was 37 weeks (range 22-41). Twelve women delivered a live-born before 36 weeks, all with a caesarean section. Among 74 women who reached 36 weeks gestation, 47 (64%) met the pre-established criteria for vaginal delivery, of whom 21 (45%) delivered vaginally. The most common reason for not having a vaginal delivery was the woman's request for a caesarean section. No cases of HIV vertical transmission occurred (0/90, 95% CI 0-4.02%).

Conclusion: Recommending vaginal delivery among HIV-infected women in selected cases was well accepted, particularly once the policy became established. Nevertheless, a high proportion of HIV-infected women will continue to require caesarean section delivery.

MeSH terms

  • Adolescent
  • Adult
  • Antiretroviral Therapy, Highly Active
  • Cohort Studies
  • Delivery, Obstetric / methods*
  • Feasibility Studies
  • Female
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • Humans
  • Infectious Disease Transmission, Vertical / prevention & control*
  • Practice Guidelines as Topic
  • Pregnancy
  • Pregnancy Complications, Infectious / therapy*
  • Pregnancy Outcome
  • Prospective Studies
  • Risk Factors